Table 2.
Neutralizing-antibody activity at each timepoint.
| Result | Measurement |
|---|---|
| NAbs pre Evusheld—% (median, IQR) Sample size—no. (%) |
92.6% (71.3–96.0) |
| NAbs post Evusheld—(% median, IQR) Samples—no. (%) |
97.3% (95.5–97.8) |
| COVID-19-positive post Evusheld—no. (%) Timeline—days (median, IQR) |
9 (8.1%) 31 (8–55) |
| NAbs 3 months post Evusheld—% (median, IQR) Sample size—no. (%) |
95.4% (93.7–97.9) 33 (30%) |
| NAbs 6 months post Evusheld—(% median, IQR) Sample size—no. (%) |
95.1% (94.9–95.7) 4 (3.6%) |
| NAbs pre second Evusheld dose—% (median, IQR) Sample size—no. (%) |
95.1% (94.8–95.9) 23 (20.7%) |
| NAbs post second Evusheld dose—% (median, IQR) Sample size—no. (%) |
95.1% (94.9–96.0) 23 (20.7%) |
| Infusion-related reactions—no. (%) | 0 (0%) |
| Major adverse events—no. (%) | 0 (0%) |
| Pain at the injection site—no. (%) | 33 (30%) |